Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California



 

Recent News and Articles on the Keywords: alzheimer's drug + drugs + alzheimers  Related to the article below (Last Update: 8/5/2008)


The Money Times
A Second Chance to Buy Wyeth?
Barron's - Aug 3, 2008
WYETH AND ITS IRISH PARTNER, ELAN, TUESDAY UNVEILED EAGERLY awaited details of a Phase II clinical trial of a promising Alzheimer's drug, bapineuzumab. ...
Alzheimer's Drugs: Investors' Impatience BusinessWeek
Elan Tanks As Buzz For New Alzheimer's Drug Dies Forbes
Elan shares fall over Alzheimer's drug results The Associated Press
Reuters - Bloomberg
all 299 news articles »  ELN - PINK:ELNCF - WYE
Alzheimer drug slows cognitive decline
Irish Times, Ireland -
A NEW DRUG has slowed cognitive decline by up to 81 per cent in Alzheimer patients during early pharmaceutical trials, it has been announced. ...
Nymox Has Global Patent Rights For Statin Drugs For The Treatment ... Medical News Today (press release)
all 2 news articles »  NYMX

TheMedGuru
Alzheimer drug puts TauRx on biotech map
Times Online, UK - Aug 3, 2008
TauRx Therapeutics, an almost unknown drugs company, has found itself at the centre of worldwide attention after details of its Rember drug for Alzheimer's ...
Scots Create Drug to Halt Alzheimer's Pill is 'Biggest ... RedOrbit
Alzheimer's disease researchers see progress on new drugs EiTB
New drug halts Alzheimer's progression, scientists discover McKnight's Long Term Care News
Dallas Morning News - The Times
all 49 news articles »

RTE.ie
MS drug fear sends Elan shares crashing
Belfast Telegraph, United Kingdom -
Earlier this week Elan also reported disappointing results from its Alzheimer's treatment AAB-001, which resulted in a share slump. ...
Health Winners & Losers: Elan TheStreet.com
Elan Jumps into Recovery Mode Investerms.com
Time to Buy Elan? Seeking Alpha
Forbes - International Herald Tribune
all 217 news articles »  ELN - BIIB - PINK:ELNCF
Alzheimer's drug trial at OHSU shows promise in some patients
Media Newswire (press release), NY -
A drug designed to remove amyloid plaques from the brain appears to help some patients with mild to moderate Alzheimer's disease, according to a clinical ...
New Alzheimer's Drug Could Be Effective, Cheap, and Unprofitable
Wired News - Jul 30, 2008
By Alexis Madrigal July 30, 2008 | 2:51:16 PMCategories: Pharmaceutical Industry An Alzheimer's drug that targets a new area of the brain's circuitry could ...
Patients could be denied 'breakthrough' Alzheimer's drug ... Telegraph.co.uk
Alzheimer's drug hailed as a 'major' development Independent
'De-Tangling' Alzheimer's Drug Shows Promise U.S. News & World Report
The Associated Press - Telegraph.co.uk
all 630 news articles »
Caution Urged on Alzheimer?s Drug Speculation
Senior-Spectrum, CA -
And Enbrel has not been approved for the treatment of Alzheimer?s disease. The use of the drug by Dr. Tobinick is ?off label? ? a term that refers to the ...

MedPage Today
Alzheimer's drug helps patients up to 18 months
CNNMoney.com - Jul 30, 2008
NEW YORK (Associated Press) - Medivation Inc.'s experimental Alzheimer's drug continues to help patients with mild and moderate forms of the brain disease ...
UPDATE 1-Medivation Alzheimer's drug helps - if used early Reuters
Baxter's Immune Boosting Drug May Help Alzheimer's (Update2) Bloomberg
Baxter boosted by drug's head start Chicago Tribune
WebMD - Reuters
all 85 news articles »  BAX - MDVN

Canada.com
Eli Lilly to release Alzheimer's drug study data
Forbes, NY - Jul 30, 2008
AP 07.30.08, 6:18 AM ET Eli Lilly and Co. will become the latest large drug maker to dissect its Alzheimer's research progress when it releases on Wednesday ...
Lilly Alzheimer's Drug Affected Brain Substance CNNMoney.com
Lilly says Alzheimer's antibody drug safe Reuters
2 drugs hold hope for dread disease Indianapolis Star
Washington Post - MarketWatch
all 105 news articles »  LLY

ABC News
Suven Life Sciences Presents Positive Preclinical Data for SUVN ...
PharmaLive.com (press release), PA -
4, 2008 ? Suven presented preclinical data for SUVN-502, its lead 5-HT6 antagonist drug candidate, at the 2008 Alzheimer's Association International ...
ABC News Medical Contributor ABC News
all 3 news articles »  BOM:530239 - NSE:E:SUVEN.EQ
Source: Google News

Nonsteroidal anti-inflammatory drugs in Alzheimer's disease -
JB Rich - Neurology, 1995 - AAN Enterprises
... Onder, A. Russo, S. Torre, and R. Bernabei Non-Steroidal Anti-Inflammatory Drug
(NSAID) Use and Alzheimer Disease in Community-Dwelling Elderly Patients Am J ...

… onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. -
JC Breitner, KA Welsh, MJ Helms, PC Gaskell, BA … - Neurobiol Aging, 1995 - ncbi.nlm.nih.gov
1995 Jul-Aug;16(4):523-30. Click here to read Delayed onset of Alzheimer's disease
with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. ...

Nerve inflammation halts trial for Alzheimer's drug. -
E Check - Nature, 2002 - ncbi.nlm.nih.gov
Nature. 2002 Jan 31;415(6871):462. Click here to read Comment in: Nature. 2002 Apr
18;416(6882):677. Nerve inflammation halts trial for Alzheimer's drug. ...

Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging -
IR Mackenzie - Neurology, 1998 - AAN Enterprises
... Academy of Neurology. ARTICLES. Nonsteroidal anti-inflammatory drug use
and Alzheimer-type pathology in aging. IR Mackenzie and DG ...

Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review … -
M Etminan, S Gill, A Samii - BMJ: British Medical Journal, 2003 - pubmedcentral.nih.gov
... PC, Kurland LT, Kokman E. Nonsteroidal anti-inflammatory drug use and Alzheimer's
disease: a case-control study in Rochester, Minnesota, 1980 through 1984. ...

A Cholesterol-Lowering Drug Reduces ?-Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's -
LM Refolo, MA Pappolla, J LaFrancois, B Malester, … - Neurobiology of Disease, 2001 - Elsevier
... Transgenic mice exhibiting an Alzheimer?s -amyloid phenotype were treated with the
cholesterol-lowering drug BM15.766 and tested for modulation of -amyloid ...

THE ROLE OF ANTI-INFLAMMATORY DRUGS IN THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE -
JCS Breitner, MD, MP H - Annual Reviews in Medicine, 1996 - Annual Reviews
... Nonsteroidal antiinflammatory drug use in Alzheimer's disease. Biol. ... 1994. Non-steroidal
anti-inflammatory drug use and risk of Alzheimer's disease. ...

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer?s disease -
M Sano, C Ernesto, RG Thomas, MR Klauber, K … - N Engl J Med, 1997 - Mass Med Soc
... Because oxidative damage plays a role in the pathogenesis of Alzheimer's disease,
antioxidant drugs could potentially delay disease progression. ...

Clinical trial of indomethacin in Alzheimer's disease -
J Rogers - Neurology, 1993 - AAN Enterprises
... Onder, A. Russo, S. Torre, and R. Bernabei Non-Steroidal Anti-Inflammatory Drug
(NSAID) Use and Alzheimer Disease in Community-Dwelling Elderly Patients Am J ...

… -tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study … -
M Sano, C Ernesto, RG Thomas, MR Klauber, K … - N Engl J Med, 1997 - ncbi.nlm.nih.gov
... A controlled trial of selegiline, alpha-tocopherol, or both as treatment for
Alzheimer's disease. The Alzheimer's Disease Cooperative Study. ...

Source: Google Scholar
 

UK court to hear Alzheimer's drugs case in June

Last Updated: 2007-05-09 13:01:27 -0400 (Reuters Health)

LONDON - Drug manufacturers challenging a decision by Britain's cost-effectiveness watchdog to restrict access to Alzheimer's drugs on the state health service will get their day in court next month.

Eisai Co Ltd and Pfizer Inc, which jointly market the top-selling such medicine Aricept, said on Wednesday the High Court had granted a request to fast track the date for a judicial review and the hearing would commence on June 25.

The companies are challenging the process by which the National Institute for Health and Clinical Excellence (NICE) reached its decision to ban anti-dementia medicines for National Health Service patients with newly diagnosed mild Alzheimer's disease.

Article continues below and (thank you)

 

It is the first time that the agency in charge of deciding which medicines are offered in the state health system in England and Wales has faced such legal action.

NICE believes drugs like Aricept do not make enough of a difference to be used at all stages of Alzheimer's disease. In future, it wants them to be prescribed only for a minority of patients with disease of moderate severity.

Anti-cholinesterase drugs such as Aricept can help but not cure some Alzheimer's patients. They are widely used in other countries, but NICE experts calculate that their cost -- around 1,000 pounds ($1,994) per patient a year -- means they are not cost-effective for most patients.

Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

 
 
 
Google
Web www.iconocast.com
 
 
Continue News With: News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

 © 2002-2006

Keywords:

Contact Iconocast